McEwen Centre for Regenerative Medicine, Toronto, Ontario, Canada.
Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2938-48. doi: 10.1161/ATVBAHA.111.232975. Epub 2011 Aug 18.
The goal of this study was to characterize the factors and conditions required for smooth muscle cell (SMC)-directed differentiation of Sox2(+) multipotent rat and human skin-derived precursors (SKPs) and to define whether they represent a source of fully functional vascular SMCs for applications in vivo.
We found that rat SKPs can differentiate almost exclusively into SMCs by reducing serum concentrations to 0.5% to 2% and plating them at low density. Human SKPs derived from foreskin required the addition of transforming growth factor-β1 or -β3 to differentiate into SMCs, but they did so even in the absence of serum. SMC formation was confirmed by quantitative reverse transcription-polymerase chain reaction, immunocytochemistry, and fluorescence-activated cell sorting, with increased expression of smoothelin-B and little to no expression of telokin or smooth muscle γ-actin, together indicating that SKPs differentiated into vascular rather than visceral SMCs. Rat and human SKP-derived SMCs were able to contract in vitro and also wrap around and support new capillary and larger blood vessel formation in angiogenesis assays in vivo.
SKPs are Sox2(+) progenitors that represent an attainable autologous source of stem cells that can be easily differentiated into functional vascular SMCs in defined serum-free conditions without reprogramming. SKPs represent a clinically viable cell source for potential therapeutic applications in neovascularization.
本研究旨在描述 Sox2(+)多能大鼠和人皮肤衍生前体细胞(SKP)向平滑肌细胞(SMC)定向分化所需的条件和因素,并确定它们是否可作为体内应用的完全功能性血管 SMC 的来源。
我们发现,通过将血清浓度降低至 0.5%至 2%并以低密度铺板,大鼠 SKP 几乎可以完全分化为 SMC。来源于包皮的人 SKP 需要添加转化生长因子-β1 或-β3 才能分化为 SMC,但即使没有血清,它们也能分化为 SMC。SMC 的形成通过定量逆转录聚合酶链反应、免疫细胞化学和荧光激活细胞分选得到证实,平滑肌素-B 的表达增加,而 telokin 或平滑肌 γ-肌动蛋白的表达很少或没有,这表明 SKP 分化为血管而不是内脏 SMC。大鼠和人 SKP 衍生的 SMC 能够在体外收缩,并且还能够在体内血管生成实验中包裹和支持新的毛细血管和更大的血管形成。
SKP 是 Sox2(+)祖细胞,代表一种可获得的自体干细胞来源,可在无血清的定义条件下轻易分化为功能性血管 SMC,而无需重编程。SKP 代表一种有临床应用前景的细胞来源,可用于促进新血管形成的治疗应用。